别名 补体C5、C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4、C5 + [10] |
简介 Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.
Derived from proteolytic degradation of complement C5, C5a anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:8182049). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. |
靶点 |
作用机制 C5抑制剂 |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2024-02-06 |
靶点 |
作用机制 C5抑制剂 |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期2023-09-25 |
靶点 |
作用机制 C5抑制剂 |
在研机构 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2023-08-18 |
开始日期2025-03-01 |
申办/合作机构 |
开始日期2024-06-01 |
申办/合作机构 |
开始日期2024-04-25 |
申办/合作机构 |